For generations, the treatment of pain has come at a cost — relief purchased with the risk of dependency, as opioids quieted suffering while quietly reshaping lives. Now, a compound called VX-548 is being studied as a more precise instrument: a pill that interrupts pain signals only at the body's outermost nerve pathways, leaving the heart and brain undisturbed. Developed by Vertex Pharmaceuticals and tested in surgical patients, it represents an early but meaningful step in a long search for pain relief that does not carry addiction as its shadow.
Experimental drug VX-548 shows promise as nonaddictive alternative to opioids
A one-job drug designed to stop pain before it reaches the brain
Mark
Why does it matter that this drug only affects peripheral nerves and not the brain or heart?
Mimi
Because opioids work everywhere in the body at once. They dull pain, yes, but they also hit the brain's reward centers, which is what creates addiction. VX-548 is designed to be a one-job drug—stop the pain signal before it even reaches the brain.
Mark
So it's like the difference between turning off a light switch versus dimming all the lights in the house?
Mimi
Exactly. Novocaine does something similar, but you can't take it as a pill because it would dim all the lights. VX-548 is selective enough that you can swallow it.
Mark
The study showed it worked better than placebo, but what about compared to opioids?
Mimi
That's the honest answer: we don't know yet. This trial wasn't designed to make that comparison directly. But there were hints—fewer side effects, fewer people quitting because it wasn't working. The real test comes in phase 3, which is happening now.
Mark
If it works, how long until patients can actually get it?
Mimi
Years, probably. Even if phase 3 goes well, the FDA still has to approve it. And then there's the question of whether it works for other kinds of pain beyond surgery. Vertex is already testing it for nerve damage pain, but that's early stage.
Mark
What's the catch? Why hasn't someone done this before?
Mimi
They didn't know these selective sodium channels existed until relatively recently. Once scientists figured out that the peripheral nerves had their own channels—1.7, 1.8, 1.9—the possibility opened up. It's the kind of thing that seems obvious in hindsight.
The Pulse
- The opioid crisis has made the hunt for nonaddictive pain relief one of medicine's most urgent open problems, and VX-548 enters that space with a targeted mechanism no oral drug has achieved before.
- Clinical trials involving over 500 post-surgery patients showed that only the highest dose of VX-548 meaningfully outperformed placebo — a promising but carefully bounded result.
- Unlike opioids, which suppress the entire nervous system, VX-548 blocks only sodium channel 1.8 in peripheral sensory nerves, producing modest side effects like headache rather than respiratory depression or dependency.
- Fewer patients abandoned VX-548 due to inadequate relief compared to those on opioids — a quiet but telling signal buried within a trial not formally designed to make that comparison.
- Phase 3 trials pitting VX-548 directly against standard opioids are now underway, and early research into its use for diabetic neuropathy suggests the drug's ambitions extend well beyond the surgical ward.
For generations, the treatment of pain has come at a cost — relief purchased with the risk of dependency, as opioids quieted suffering while quietly reshaping lives. Now, a compound called VX-548 is being studied as a more precise instrument: a pill that interrupts pain signals only at the body's outermost nerve pathways, leaving the heart and brain undisturbed. Developed by Vertex Pharmaceuticals and tested in surgical patients, it represents an early but meaningful step in a long search for pain relief that does not carry addiction as its shadow.
In the long effort to treat pain without creating dependency, researchers have been studying VX-548 — a pill developed by Boston-based Vertex Pharmaceuticals that works by blocking a sodium channel found only in the body's peripheral sensory nerves. The concept echoes novocaine, which dentists have used for decades to stop pain signals, but novocaine is a blunt instrument: given as a pill, it would interfere with the heart and brain. Scientists have only recently identified sodium channels exclusive to peripheral nerves, and VX-548 targets one of them — channel 1.8 — with enough precision to be taken orally.
To test whether that precision translates into real relief, researchers ran two parallel trials: one with 303 patients recovering from tummy tuck surgery, another with 274 bunion surgery patients. Both groups took their assigned medication — VX-548 at varying doses, a hydrocodone-acetaminophen opioid, or placebo — for 48 hours post-surgery. Only the highest dose of VX-548 outperformed placebo, reducing pain scores meaningfully over that period. Side effects were mild, and fewer patients stopped taking it due to inadequate relief compared to those on opioids. The findings were published in the New England Journal of Medicine in August 2023.
Experts are encouraged but measured. Dr. Mark Wallace of UC San Diego called it an early exploration of what could become an important new class of medications. Yale neurologist Dr. Stephen Waxman, who commented on the study, noted that the drug's mechanism gives no reason to expect addiction. Questions remain — about whether targeting multiple peripheral channels might work better, and whether VX-548 can address harder-to-treat conditions like neuropathic pain. Vertex has already begun an early trial for diabetic neuropathy. Phase 3 trials comparing VX-548 directly against opioids are underway, and those results will determine whether this precision approach can genuinely compete with the drugs it hopes to replace.
In the search for pain relief that doesn't carry the weight of addiction, researchers have been studying a compound called VX-548—a pill designed to interrupt pain signals at a very specific point in the body's nervous system. The drug works by blocking a sodium channel found only in the peripheral sensory nerves, the ones that carry pain messages to the brain. Unlike opioids, which flood the entire system and create dependency, VX-548 is engineered to affect only those outer nerve pathways, leaving the heart and brain untouched.
The concept isn't entirely new. Novocaine, the anesthetic dentists have used for decades, works on a similar principle—blocking sodium channels to stop pain signals. But novocaine and its cousins like lidocaine are blunt instruments. They block sodium channels indiscriminately, which means if you tried to give them as a pill, they'd interfere with the heart and brain. That's why they're injected directly into the area needing relief. Scientists have only recently discovered that certain sodium channels exist exclusively in the peripheral nerves. Three have been identified so far: 1.7, 1.8, and 1.9. VX-548, being developed by Boston-based Vertex Pharmaceuticals, targets the 1.8 channel.
To test whether this precision actually translates into pain relief, researchers ran two parallel trials. In one, 303 patients undergoing tummy tucks were randomly assigned after surgery to receive either VX-548 at a high or moderate dose, a standard opioid painkiller containing hydrocodone and acetaminophen, or a placebo. A second trial followed 274 patients having bunion surgery, with similar assignments but three different doses of the experimental drug. Both groups took their assigned medication for 48 hours following surgery. The results showed that only the highest dose of VX-548 outperformed placebo, reducing patients' pain intensity scores more substantially over the two-day period. The side effects were modest—mainly headache and constipation—nothing like the respiratory depression and addiction potential of opioids.
While the study wasn't formally designed to pit VX-548 against hydrocodone, some encouraging signals emerged. The experimental drug appeared to cause fewer side effects overall. More tellingly, fewer patients stopped taking VX-548 because it wasn't working, compared to those on opioids. The findings were published in the New England Journal of Medicine in August 2023, accompanied by commentary from Dr. Stephen Waxman, a neurology professor at Yale, who explained the science without being involved in the trial itself. Waxman emphasized that based on how the drug works—blocking only those peripheral channels—there's no reason to expect it would be addictive.
But researchers are cautious about drawing sweeping conclusions. Dr. Mark Wallace, a pain specialist at UC San Diego, called the study an early exploration of what could become an exciting new class of medications in a field that desperately needs options. The opioid crisis has made the search for alternatives urgent, yet the work is far from finished. Questions remain about whether blocking multiple peripheral sodium channels might be even more effective. And while these trials focused on post-surgery pain, there are other forms of pain—neuropathic pain from nerve damage, for instance—that are far harder to treat. Vertex has already begun an early trial of VX-548 for diabetic neuropathy. Waxman himself is confident that nonaddictive pain medications will eventually emerge from this research, though he cautions it will take time. The phase 3 trials comparing VX-548 directly against standard opioids are already underway, and those results will tell us whether this precision approach to pain relief can actually compete with the drugs it's meant to replace.
Notable Quotes
These findings are an important step forward in showing proof-of-principle that a selective sodium channel blocker can relieve acute pain.— Dr. Stephen Waxman, Yale University School of Medicine
I'm confident that we will have a new class of nonaddictive pain medications, but it will take some time.— Dr. Stephen Waxman
Want the full story?
Read the original at UPI News ↗
Health & Medicine